225 related articles for article (PubMed ID: 23894194)
1. Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
Manna S; Singha B; Phyo SA; Gatla HR; Chang TP; Sanacora S; Ramaswami S; Vancurova I
J Immunol; 2013 Sep; 191(5):2837-46. PubMed ID: 23894194
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Singha B; Gatla HR; Manna S; Chang TP; Sanacora S; Poltoratsky V; Vancura A; Vancurova I
J Biol Chem; 2014 Jan; 289(5):2687-700. PubMed ID: 24337575
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
[TBL] [Abstract][Full Text] [Related]
4. Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Sanacora S; Urdinez J; Chang TP; Vancurova I
Biochem Biophys Res Commun; 2015 May; 460(2):375-9. PubMed ID: 25791477
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
6. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
7. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Lee KH; Jeong J; Yoo CG
J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Singha B; Phyo SA; Gatla HR; Vancurova I
Methods Mol Biol; 2014; 1172():295-304. PubMed ID: 24908316
[TBL] [Abstract][Full Text] [Related]
9. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
12. Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages.
Sanacora S; Chang TP; Vancurova I
Methods Mol Biol; 2014; 1172():315-27. PubMed ID: 24908318
[TBL] [Abstract][Full Text] [Related]
13. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.
Ikezoe T; Yang Y; Saito T; Koeffler HP; Taguchi H
Cancer Sci; 2004 Mar; 95(3):271-5. PubMed ID: 15016328
[TBL] [Abstract][Full Text] [Related]
18. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T
Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
20. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B
Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]